Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
VV
Vivos Therapeutics, Inc. Common Stock
VVOS
Mkt Cap
$2.6M
Volume
1.61M
Next Earnings
November 18th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
VV
VVOS
VV
Vivos Therapeutics, Inc. Common Stock
VVOS
News
·
Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers
Mkt Cap
$2.9M
Volume
1.61M
Next Earnings
November 18th
Chart
Financials
Earnings
News
About
Insider
Filings
Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers
Vivos Therapeutics announced a 212% increase in average weekly new patient referrals at its Nevada Sleep & Airway Medicine Centers over the past six weeks compared to the prior six-week period. The company opened a new 8,100 sq. ft. state-of-the-art facility in Henderson, Nevada on August 27, 2026, and expects significant revenue growth as the facility becomes fully operational and processes the increased patient volume.
GlobeNewswire Inc. · Aug 25, 2026
Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026
Vivos Therapeutics (NASDAQ: VVOS), a medical device company specializing in obstructive sleep apnea treatment, announced that CEO Kirk Hunstman will present at The Small Cap Showcase & WTR Insights on June 9, 2026, in New York City. The company will participate in investor meetings and deliver a corporate presentation at 11:30 am ET.
GlobeNewswire Inc. · Jun 8, 2026
Global Sleep Apnea Devices Market is Expected to Cross the USD 15 Billion Mark by 2032 | DelveInsight
The global sleep apnea devices market is projected to grow from USD 9.5 billion in 2024 to USD 15.8 billion by 2032, with a CAGR of approximately 6%. Growth is driven by rising OSA prevalence, technological advancements, increased awareness, and expanding healthcare infrastructure. North America leads the market with over 45% share, while Asia-Pacific emerges as a major growth driver. Key players include Philips, ResMed, and Fisher & Paykel Healthcare.
GlobeNewswire Inc. · Jan 21, 2026
Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds
Vivos Therapeutics (NASDAQ: VVOS) announced the closing of a warrant exercise that generated approximately $4.64 million in gross proceeds. The company exercised 1,982,356 outstanding warrants at a reduced price of $2.34 per share and issued new unregistered warrants to purchase 3,964,712 shares at $2.09 per share. Net proceeds will be used for working capital and general corporate purposes.
GlobeNewswire Inc. · Jan 20, 2026
Vivos Therapeutics to Participate in Online Fireside Chat with Water Tower Research on December 16, 2025, at 11 am EST
Vivos Therapeutics, a medical device company specializing in sleep-related breathing disorders, will participate in a fireside chat to discuss its strategic business model, market opportunities, and growth strategies.
GlobeNewswire Inc. · Dec 15, 2025
Vivos Reports 7% Sales Drop
Vivos Therapeutics reported Q2 2025 results with declining revenue of $3.8 million, a strategic shift towards medical provider alliances, and increased operating expenses following the Sleep Center of Nevada acquisition.
The Motley Fool · Aug 20, 2025
Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model
8 Out of 10 Newly Diagnosed OSA Patients Choose Oral Appliance Therapy Over CPAP and Preferred Vivos’ Flagship CARE Oral Medical Devices 5 to 1 Over Traditional Oral Appliances 8 Out of 10 Newly Diagnosed OSA Patients Choose Oral Appliance Therapy Over CPAP and Preferred Vivos’ Flagship CARE Oral Medical Devices 5 to 1 Over Traditional Oral Appliances
GlobeNewswire Inc. · Jun 27, 2024
Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance
Alliance with Sleep Treatment Provider in Colorado Marks Critical Pivot in Vivos’ Marketing and Distribution Model Aimed at Enhancing Revenue Streams and Potential Profit
GlobeNewswire Inc. · Jun 12, 2024
Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call
Call Scheduled for Today, Tuesday, May 14, 2024 at 5:00 pm ET Call Scheduled for Today, Tuesday, May 14, 2024 at 5:00 pm ET
GlobeNewswire Inc. · May 14, 2024
Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
First Medicare-Accepted Oral Appliance Treatment for All Severities of Obstructive Sleep Apnea in Adults First Medicare-Accepted Oral Appliance Treatment for All Severities of Obstructive Sleep Apnea in Adults
GlobeNewswire Inc. · Apr 9, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
VV
VVOS
Vivos Therapeutics, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
VVOS
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any VVOS yet.
Related Tickers
Earnings